PH12020550795A1 - Methods of using and compositions containing dulaglutide - Google Patents

Methods of using and compositions containing dulaglutide

Info

Publication number
PH12020550795A1
PH12020550795A1 PH1/2020/550795A PH12020550795A PH12020550795A1 PH 12020550795 A1 PH12020550795 A1 PH 12020550795A1 PH 12020550795 A PH12020550795 A PH 12020550795A PH 12020550795 A1 PH12020550795 A1 PH 12020550795A1
Authority
PH
Philippines
Prior art keywords
methods
compositions containing
dulaglutide
containing dulaglutide
doses
Prior art date
Application number
PH1/2020/550795A
Other languages
English (en)
Inventor
David Andrew Cox
Zvonko Milicevic
Lai San Tham
Andrew Gordon Werner
David Bradley Woodward
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12020550795(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PH12020550795A1 publication Critical patent/PH12020550795A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
PH1/2020/550795A 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide PH12020550795A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (1)

Publication Number Publication Date
PH12020550795A1 true PH12020550795A1 (en) 2021-04-19

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2020/550795A PH12020550795A1 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Country Status (21)

Country Link
US (2) US11576950B2 (cg-RX-API-DMAC7.html)
EP (1) EP3713593A2 (cg-RX-API-DMAC7.html)
JP (3) JP7221956B2 (cg-RX-API-DMAC7.html)
KR (2) KR102589234B1 (cg-RX-API-DMAC7.html)
CN (2) CN111356472A (cg-RX-API-DMAC7.html)
AU (2) AU2018372709B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020007817A2 (cg-RX-API-DMAC7.html)
CL (1) CL2020001252A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200202A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000104A (cg-RX-API-DMAC7.html)
EA (1) EA202090971A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20026436A (cg-RX-API-DMAC7.html)
IL (1) IL274563B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200126B1 (cg-RX-API-DMAC7.html)
MA (1) MA50798A (cg-RX-API-DMAC7.html)
MX (1) MX2020005231A (cg-RX-API-DMAC7.html)
PE (1) PE20200847A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550795A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003687RA (cg-RX-API-DMAC7.html)
UA (1) UA127588C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019103875A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ. ホフマン-ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
AU2022298662B2 (en) 2021-06-23 2025-06-05 Eli Lilly And Company An incretin analog for use in glycemic control and weight management

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
JP2008525452A (ja) 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Glp−1類似体融合蛋白質製剤
KR20100020516A (ko) * 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Glp-1-fc 융합 단백질 제제
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
US20200171129A1 (en) 2017-06-01 2020-06-04 Eli Lilly And Company Therapeutic uses of dulaglutide

Also Published As

Publication number Publication date
JP7221956B2 (ja) 2023-02-14
DOP2020000104A (es) 2020-08-31
UA127588C2 (uk) 2023-10-25
BR112020007817A2 (pt) 2020-10-06
WO2019103875A3 (en) 2019-07-25
MA50798A (fr) 2020-09-30
KR102589234B1 (ko) 2023-10-16
EP3713593A2 (en) 2020-09-30
CN111356472A (zh) 2020-06-30
AU2018372709A1 (en) 2020-05-14
SG11202003687RA (en) 2020-06-29
US11576950B2 (en) 2023-02-14
KR20200076705A (ko) 2020-06-29
JP2024056908A (ja) 2024-04-23
WO2019103875A2 (en) 2019-05-31
PE20200847A1 (es) 2020-08-18
MX2020005231A (es) 2020-08-24
US20240189394A1 (en) 2024-06-13
ECSP20026436A (es) 2020-06-30
JOP20200126A1 (ar) 2020-05-21
JOP20200126B1 (ar) 2024-04-18
AU2022203372A1 (en) 2022-06-09
CL2020001252A1 (es) 2020-10-30
JP7818412B2 (ja) 2026-02-20
AU2022203372B2 (en) 2025-04-10
IL274563A (en) 2020-06-30
AU2018372709B2 (en) 2022-04-28
US20200330558A1 (en) 2020-10-22
JP2022062153A (ja) 2022-04-19
CR20200202A (es) 2020-08-20
CN120478602A (zh) 2025-08-15
CA3082625A1 (en) 2019-05-31
EA202090971A1 (ru) 2020-08-07
IL274563B2 (en) 2023-12-01
KR20220146656A (ko) 2022-11-01
NZ763815A (en) 2023-11-24
JP2021502379A (ja) 2021-01-28
IL274563B1 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
PH12018500950B1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
PH12017502255B1 (en) Nrf2 regulators
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MY192588A (en) Pharmaceutical compounds
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
JOP20200126A1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
PH12019502469A1 (en) Novel fragrance compositions and products with mood enhancing effects
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IN2014CH00840A (cg-RX-API-DMAC7.html)
MX368011B (es) Composiciones para el tratamiento de la hipertensión y/o la fibrosis.
MX2020002793A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
MX2020003763A (es) Composiciones de flumioxazina y metodos para usar las mismas.
PH12017501897A1 (en) 2-thiopyrimidinones